| Affiliation: | Jacqueline A Maybin PhD MRCOG is a Clinical Lecturer in Obstetrics and Gynaecology at the MRC Centre for Reproductive Health, University of Edinburgh, The Queen''s Medical Research Institute, Edinburgh, UK. Conflicts of interest: none declared; Malcolm G Munro MD FRCS FACOG is Professor, Department of Obstetrics and Gynecology at David Geffen School of Medicine at UCLA, Kaiser Permanente, Los Angeles Medical Center, Los Angeles, CA, USA. Conflicts of interest: MM has the following disclosures: Grant-Research Support in AUB Treatment (Bayer Women''s Health, EndoSee); Consultant/Advisory Boards on Abnormal Uterine Bleeding (Karl Storz, AMAG Pharmaceuticals, Abbvie Inc, Ethicon Women''s Health & Urology, Boston Scientific, Bayer Women''s Health, Gynesonics, Inc, Channel Medical), Vifor Inc; Equity Ownership/Stock Options (Gynesonics, Inc, Channel Medical); Ian S Fraser AO DSc MD is Professor in Reproductive Medicine, Department of Obstetrics, Gynaecology and Neonatology at Queen Elizabeth II Research Institute for Mothers and Infants, The University of Sydney, NSW, Australia. Conflicts of interest: ISF has received Grant/Research Support in AUB Treatment and Contraception Trials (Bayer Schering Pharma, Schering Plough); Speakers Bureau on AUB Treatment and Long-Acting Contraception (Bayer Schering Pharma, Schering Plough, Daiichi Sankyo); Advisory Board on AUB Treatment with Qlaira and Implant Removal (Bayer Schering Pharma, Schering Plough); Hilary OD Critchley MD FRCOG FRSE FMedSci is Professor of Reproductive Medicine at the MRC Centre for Reproductive Health, The University of Edinburgh, The Queen''s Medical Research Institute, Edinburgh, UK. Conflicts of interest: HC has received Grant/Research Support in AUB Treatment (TAP Pharmaceuticals, Bayer Pharma AG); Speakers Bureau on AUB Treatment (Bayer Pharma AG, Preglem/Gedeon-Richter); Consultancy/ Advisory Board on AUB Treatment (Bayer Pharma AG, Preglem/Gedeon-Richter, Vifor Pharma) |
